

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5

**Isobogram of cetuximab vs Compound 2 in  
GEO cells**




FIG. 6

**Isobogram of gefitinib vs.  
Compound 2 in RD1 cells**




FIG. 7






FIG. 8



9/17


FIG. 9



10/17

FIG. 10


**Compound 1 vs etoposide in  
MDA-Pca-2b cells**



11/17


FIG. 11

Compound 1 vs cisPLATIN in  
RD1 cells



12/17


FIG. 12



13/17

FIG. 13

**Fraction Plot for IGF1R inhibitor ratios with Scr inhib. in HT-29 cells**



14/17

FIG. 14

Fraction Plot for IGF1R inhibitor ratios with Src inhib. in Colo205 cells




FIG. 15

**Isobogram of MEK inhibitor vs IGF1R inhibitor**




FIG. 16

**Fraction Plot for IGF1R inhibitor ratios with pan Her inhibitor in  
Colo205 cells**




FIG. 17

